Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study

Trifilio, Steven; Welles, Colleen; Seeger, Kristin; Mehta, Suresh L.; Fishman, Mary Anne; McGowan, Katherine; Strejcek, Kathryn; Eiten, Emily; Pirotte, C; Lucier, Elizabeth; DeFrates, Sean; Mehta, Jayesh

doi:10.1016/j.clml.2017.06.012

Cited by 21 publications

(26 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results from the noncomparative trials confirmed the efficacy of the three-drug regimen that was mentioned above [12,15,[18][19][20]. Data from the trial comparing olanzapine-containing therapy with an aprepitant or fosaprepitant-containing threedrug regimen [14] are discussed below.…”

Section: Drug-focused Overviewsupporting

confidence: 53%

“…Nevertheless, in the last years, data on the acute and delayed emetogenicity of HDMel were reported in articles that presented the results of clinical trials evaluating the efficacy of new antiemetic drugs. Four detailed articles [11][12][13][14] evaluating the acute emetogenicity of HDMel in patients undergoing CINV prophylaxis with different schedules reported a low emesis incidence (0-41%). Other research on HDMel reported delayed vomiting as moderately frequent (12-66%), despite adequate prophylaxis [11,[13][14][15][16].…”

Section: Melphalan Emetogenicity During Transplantsmentioning

confidence: 99%

“…Four detailed articles [11][12][13][14] evaluating the acute emetogenicity of HDMel in patients undergoing CINV prophylaxis with different schedules reported a low emesis incidence (0-41%). Other research on HDMel reported delayed vomiting as moderately frequent (12-66%), despite adequate prophylaxis [11,[13][14][15][16]. Finally, our analysis of the literature showed a similar rate of CINV in the two melphalan schedules (MEL200×1 and MEL100×2).…”

Section: Melphalan Emetogenicity During Transplantsmentioning

confidence: 99%

“…5HT3RA 5HT3RAs are recommended by guidelines for CINV prophylaxis in autologous SCT, as well as for highly emetogenic drugs as part of a three-drug combination (aprepitant + 5HT3RA + dexamethasone) [4,8,9]. In the setting of HDMel, palonosetron was investigated in five trials [7,11,13,15,20], granisetron in three trials [12,17,19], and ondansetron in three trials [14,16,18]. The efficacy of different 5HT3RA drugs was not evaluated in the setting of HDMel; therefore, they should perhaps be considered equivalent in terms of efficacy for CINV prevention.…”

Section: Drug-focused Overviewmentioning

confidence: 99%

“…Aprepitant and Fosaprepitant As for 5HT3RA, NK1RAs are recommended for CINV prophylaxis in autologous SCT and highly emetogenic chemotherapy in combination with 5HT3RA and dexamethasone. In the setting of HDMel, aprepitant or fosaprepitant were investigated in eight different trials [12,[14][15][16][17][18][19][20]. Two trials compared a three-drug regimen (aprepitant or fosaprepitant +5HT3 + dexamethasone) with a two-drug regimen (5HT3RA + dexamethasone), concluding that the three-drug regimen was more effective [16,17].…”

Section: Drug-focused Overviewmentioning

confidence: 99%

See 4 more Smart Citations

Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions

Tendas

Marchesi²,

Mengarelli³

et al. 2018

Support Care Cancer

View full text Add to dashboard Cite

Introduction High-dose melphalan (HDMel) is the most common conditioning chemotherapy regimen for autologous stem cell transplantation (SCT) in patients affected by multiple myeloma (MM). No consensus exists for the emetogenicity or prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in this regimen. Methods Data on the incidence and efficacy/safety of CINV prophylaxis among patients affected by MM undergoing autologous SCT with the HDMel regimen was extracted from electronic databases and analyzed. Results Eleven studies involving multiple CINV prophylaxis regimens were identified and included. No consensus on HDMel emetogenicity was reached, but most studies summarized the emetogenicity as moderate-high risk. An aprepitant-based threedrug regimen (aprepitant + serotonin receptor antagonist (5HT3RA) + dexamethasone) showed better efficacy than a two-drug regimen (5HT3RA + dexamethasone) for CINV prevention without increasing the frequency in adverse events. Conclusions The aprepitant-based three-drug regimen should be the regimen of choice for CINV prophylaxis for MM patients undergoing autologous SCT with HDMel conditioning. Keywords Chemotherapy-induced nausea and vomiting. Stem cell transplantation. High-dose melphalan. Aprepitant. Quality of life * Andrea Tendas

show abstract

Section: Drug-focused Overviewsupporting

confidence: 53%

Section: Melphalan Emetogenicity During Transplantsmentioning

confidence: 99%

Section: Melphalan Emetogenicity During Transplantsmentioning

confidence: 99%

Section: Drug-focused Overviewmentioning

confidence: 99%

Section: Drug-focused Overviewmentioning

confidence: 99%

See 3 more Smart Citations

Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions

Tendas

Marchesi²,

Mengarelli³

et al. 2018

Support Care Cancer

View full text Add to dashboard Cite

show abstract

Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs

et al. 2020

View full text Add to dashboard Cite

A survey within hematopoietic stem cell transplant (HSCT) centres of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) was performed in order to describe current antiemetic prophylaxis in patients undergoing HSCT. The multicentre survey was performed by questionnaire, covering the main areas on chemotherapy induced nausea and vomiting (CINV): antiemetic prophylaxis guidelines used, antiemetic prophylaxis in different conditioning regimens, methods of CINV evaluation. The survey was carried out in November 2015 [before the publication of the Multinational Association of Supportive Care in Cancer (MASCC)/ European Society for Medical Oncology (ESMO) specific guidelines on antiemetic prophylaxis in HSCT] and its was repeated six months later. The results show a remarkable heterogeneity of prophylaxis among the various centers and a significant difference between the guidelines and the clinical practice. In the main conditioning regimens, the combination of a serotonin3 receptor antagonist (5-HT3-RA) with dexamethasone and neurokin1 receptor antagonist (NK1-RA), as recommended by MASCC/ESMO guidelines, increased from 0-14% (before the publication of the guidelines) to 10-25% (after the publication of the guidelines). This study shows a lack of compliance with specific antiemetic guidelines, resulting mainly in under-prophylaxis. Concerted strategies are required to improve the current CINV prophylaxis, to draft shared common guidelines and to increase the knowledge and the adherence to the current recommendations for CINV prophylaxis in the specific field of HSCT.

show abstract

Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation

et al. 2020

View full text Add to dashboard Cite

Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study

Cited by 21 publications

References 13 publications

Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions

Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions

Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs

Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation

Contact Info

Product

Resources

About